The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: A pilot study

Journal of Women's Health

Volumn 20, Issue 6, 2011, Pages 971-976

  Pontikis, Charalambos ^a   Yavropoulou, Maria P ^a   Toulis, Konstantinos A ^a   Kotsa, Kalliopi ^a   Kazakos, Kyriakos ^a   Papazisi, Aleka ^a   Gotzamani Psarakou, Anna ^a   Yovos, John G ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; GREECE; HUMANS; INCRETINS; INSULIN; OBESITY; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; THINNESS; YOUNG ADULT;

EID: 79959294951     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2272     Document Type: Article

References (36)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998;83:3078-3082. (Pubitemid 28500937)
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar- Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438. (Pubitemid 32269197)
3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
4. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-896. (Pubitemid 34756169)
5. Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic syndrome and polycystic ovary syndrome.and vice versa. Arq Bras Endocrinol Metabol 2009;53:227-237.
6. Legro RS, Kunselman AR, DodsonWC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169. (Pubitemid 29036695)
7. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuang-soongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Intl J Gynaecol Obstet 2001;75:177-184. (Pubitemid 33010767)
8. Toulis KA, Goulis DG, Kolibianakis EM, Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: A systematic review and a meta-analysis. Fertil Steril 2009;92:667-677
9. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 2008;26:39-44.
10. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007;92:4609-4614. (Pubitemid 350223434)
11. Morales AJ, Laughlin GA, Bu? tzow T, Maheshwari H, Baumann G. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features. J Clin Endocrinol Metab 1996;81:2854-2864. (Pubitemid 26326301)
12. Kassi E, Diamanti-Kandarakis E. The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome. J Endocrinol Invest 2008;31:1124-1131.
13. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157. (Pubitemid 46711096)
14. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913. (Pubitemid 30647076)
15. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metabol 2004;287:E199-E206. (Pubitemid 38943883)
16. Elahi D, Andersen DK, Muller DC, Tobin JD, Brown JC, Andres R. The enteric enhancement of glucose-stimulated insulin release. The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus. Diabetes 1984;33:950-957.
17. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348.
18. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type II diabetes mellitus. Am Surgeon 2004;70:1-4.
19. Gama R, Norris F, Wright J, et al. The entero-insular axis in polycystic ovarian syndrome. Ann Clin Biochem 1996;33:190-195. (Pubitemid 26178695)
20. Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome. Eur J Endocrinol 2008;159:121-127.
21. Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: Roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009;58:586-593.
22. The Rotterdam ESHRE/ASRM-sponsored PCOS ConsensusWorkshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
23. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410. (Pubitemid 32269192)
24. Espinós-Gómez JJ, Corcoy R, Calaf J. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:199-204.
25. Panidis D, Macut D, Farmakiotis D, et al. Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006;127:99-105. (Pubitemid 43947438)
26. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947. (Pubitemid 26083951)
27. Tomasik PJ, Sztefko K, Malek A. GLP-1 as a satiety factor in children with eating disorders. Horm Metab Res 2002;34:77-80. (Pubitemid 34208314)
28. Waldhaeusl W, Bratusch-Marrain P, Gasic B, Korn A, Nowotny P. Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 1979;17:221-227. (Pubitemid 10189641)
29. Faber OK, Madsbad S, Kehlet H, Binder C. Pancreatic beta cell secretion during oral and intravenous glucose administration. Acta Med Scand 1979;624(Suppl):61-64. (Pubitemid 9127202)
30. Gibby OM, Hales CN. Oral glucose decreases hepatic extraction of insulin. BMJ 1983;286:921-923. (Pubitemid 13152755)
31. Madsbad S, Kehlet H, Hilsted J, Tronnier B. Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose. Diabetes 1983;32:436-438. (Pubitemid 13129963)
32. Kuzuya T, Matsuda A. Disappearance rate of endogenous human C-peptide from blood. Diabetologia 1976;12:519-521.
33. Polonsky K, Rubenstein AH. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes 1984;33:486-493.
34. Rubenstein AH, Clark JL, Melani F, Steiner DF. Secretion of proinsulin C-peptide by pancreatic β cells and its circulation in blood. Nature 1969;224:697-699.
35. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52. (Pubitemid 16162741)
36. Cataland S, O'Dorisio TM. Pathology of gastric inhibitory polypeptide. In: van Wimersma TjB, ed. The entero-insular axis. Geneva, Switzerland: S. Kargers, 1980:145-154.